Economic evaluation in the context of rare diseases: is it possible?

Cadernos de Saúde Pública

Everton Nunes Da Silva¹  Tanara Rosângela Vieira Sousa¹ 

关键词: Cost-Effectiveness Evaluation;    Rare Diseases;    Health Economics;    Evaluación de Costo-Efectividad;    Enfermedades Raras;    Economía de la Salud;    Avaliação de Custo-Efetividade;    Doenças Raras;    Economia da Saúde;   

DOI  :  10.1590/0102-311X00213813

来源: SciELO

【 摘 要 】

This study analyzes the available evidence on the adequacy of economic evaluation for decision-making on the incorporation or exclusion of technologies for rare diseases. The authors conducted a structured literature review in MEDLINE via PubMed, CRD, LILACS, SciELO, and Google Scholar (gray literature). Economic evaluation studies had their origins in Welfare Economics, in which individuals maximize their utilities based on allocative efficiency. There is no widely accepted criterion in the literature to weigh the expected utilities, in the sense of assigning more weight to individuals with greater health needs. Thus, economic evaluation studies do not usually weigh utilities asymmetrically (that is, everyone is treated equally, which in Brazil is also a Constitutional principle). Healthcare systems have ratified the use of economic evaluation as the main tool to assist decision-making. However, this approach does not rule out the use of other methodologies to complement cost-effectiveness studies, such as Person Trade-Off and Rule of Rescue.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License